Importance of PM|AM Split Dosing

PM|AM Split Dosing with MoviPrep

Improving the quality of your colonoscopy prep

MoviPrep was the first polyethylene glycol (PEG)–based osmotic prep approved by the FDA as a PM|AM split-dosing regimen, in which you take the first dose of your colonoscopy prep the day before the procedure and complete the prep on the day of the procedure.

Research shows that the split-dosing regimen improves the overall effectiveness and tolerability of the colonoscopy prep. In fact, the American College of Gastroenterology (ACG) now recommends split dosing to improve the quality of bowel preparations and colonoscopy. Completing the second part of your prep on the day of your colonoscopy helps cleanse the colon of any waste matter that has accumulated overnight. This has been shown to leave you with a cleaner colon than evening-only colonoscopy preps.

Depending on the time of your procedure, taking MoviPrep with a PM|AM split-dosing regimen may require you to wake up early in the morning to complete your prep. While this may seem like an inconvenience, think of it as time well spent toward proactively managing your colon health. In fact, when informed of the importance of a quality colonoscopy prep, 85% of patients surveyed said they would be willing to wake up as early as 2 or 3 AM for the second dose.

Indication for MOVIPREP

MOVIPREP® (PEG-3350, sodium sulfate, sodium chloride, potassium chloride, sodium ascorbate and ascorbic acid for oral solution) is an osmotic laxative indicated for cleansing of the colon as a preparation for colonoscopy in adults 18 years of age or older.

Important Safety Information about MOVIPREP

Do not take MOVIPREP® (PEG-3350, sodium sulfate, sodium chloride, potassium chloride, sodium ascorbate and ascorbic acid for oral solution) if you have a gastrointestinal (GI) obstruction (a blockage in your bowel), bowel perforation (an opening in the wall of your stomach or intestine), gastric retention (problems with food and fluid emptying from your stomach), ileus (bowel muscle unable to move stomach contents), toxic colitis (damage to the thickness of the intestinal wall) or toxic megacolon (an extremely dilated or distended colon with fever and/or abdominal pain at times), or if you have a known allergy to MOVIPREP or any of its components.

It is important to drink sufficient liquids before, during, and after the use of MOVIPREP. Liquid and blood salt changes can lead to serious side effects including abnormal heartbeats, seizures, and kidney problems. Talk to your doctor before taking MOVIPREP if you take any medications that increase the risk of blood salt abnormalities or if you have known or suspected low blood salt (sodium) level (hyponatremia).

If you have kidney problems or if you take medication that affects kidney function, talk to your doctor before taking MOVIPREP.

If you have suspected bowel blockage or a suspected opening in the wall of your stomach or intestine, talk to your doctor before taking MOVIPREP.

Talk to your doctor before taking MOVIPREP if you have problems swallowing, if you have gastric reflux, or if you are predisposed to aspiration.

If you have a condition that destroys red blood cells called glucose-6-phosphate dehydrogenase (G6PD) deficiency, talk to your doctor before taking MOVIPREP.

Please be advised that MOVIPREP contains 131 mg of phenylalanine per treatment.

If you are pregnant or planning to become pregnant, talk to your doctor before taking MOVIPREP.

In clinical studies with MOVIPREP, the most common side effects for split dosing were malaise (feeling uneasy), nausea, stomach (abdominal) pain, vomiting, and upper stomach pain. The most common side effects for evening only dosing were stomach swelling (abdominal distension), anal discomfort, thirst, nausea, stomach (abdominal) pain, sleep disorder, rigors (body shakes), hunger, malaise (feeling uneasy), vomiting, and dizziness.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch/ or call 1-800-FDA-1088.

For product information, adverse event reports, and product complaint reports, please contact:

Salix Product Information Call Center
Phone: 1-800-508-0024
Fax: 1-510-595-8183
Email: salix@medcomsol.com

Please see complete Prescribing Information for MOVIPREP. pdf icon

For Dummies is a registered trademark of John Wiley & Sons, Inc.

Use of this site signifies your agreement to the Terms of Use. Privacy Policy.
©2014 Salix Pharmaceuticals, Inc. All rights reserved. MOV 13/23
8510 Colonnade Center Drive, Raleigh, NC 27615 USA T: 919-862-1000, F: 919-862-1095